Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo khoa học: "Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis"

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis | BioMed Central Journal of Hematology Oncology Open Access Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine a retrospective analysis Bernardo HL Goulart1 Jeffrey W Clark1 Gregory Y Lauwers2 David P Ryan1 Nina Grenon1 Alona Muzikansky3 and Andrew X Zhu 1 4 Address division of Hematology Oncology Biostatistics Center Massachusetts General Hospital Harvard Medical School Boston MA USA 2Department of Pathology Biostatistics Center Massachusetts General Hospital Harvard Medical School Boston MA USA 3Biostatistics Center Massachusetts General Hospital Harvard Medical School Boston MA USA and Massachusetts General Hospital Cancer Center 55 Fruit Street POB 232 Boston MA USA Email Bernardo HL Goulart - bhg@u.washington.edu Jeffrey W Clark - jclark@partners.org Gregory Y Lauwers - glauwers@partners.org David P Ryan - dpryan@partners.org Nina Grenon - ngrenon@partners.org Alona Muzikansky - amuzikansky@partners.org AndrewXZhu - azhu@partners.org Corresponding author Published 16 March 2009 Received 5 January 2009 Journal of Hematology Oncology 2009 2 13 doi 10.1186 1756-8722-2-13 Accepted 16 March 2009 This article is available from http www.jhoonline.Org content 2 1 13 2009 Goulart et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Metastatic pancreatic adenocarcinoma has a short median overall survival OS of 5-6 months. However a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations. Methods We identified 20 patients with metastatic or recurrent pancreatic adenocarcinoma who received single-agent gemcitabine and had an OS longer than 1 year. .

TÀI LIỆU LIÊN QUAN

báo cáo hóa học: " Health-related Quality of Life in Vacuum-Assisted Breast Biopsy: short-term effects, long-term effects and predictors"

Báo cáo khoa học: "Automatically Generating Term-frequency-induced Taxonomies"

Báo cáo khoa học: "Short-term variations and long-term changes in oak productivity in northeastern France. The role of climate and atmospheric CO 2"

Báo cáo y học: "Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity"

Báo cáo y học: "Ethics review: Long-term outcomes and clinical predictors of hospital mortality in very long stay intensive care unit patients: a cohort study"

Báo cáo khoa học: "Long-term sequelae of critical illness: memories and healthrelated quality of life"

Báo cáo khoa học: "Corticosteroids increased short and long-term mortality in adults with traumatic head injury"

Báo cáo khoa học: " Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based stud"

Báo cáo khoa học: " Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma"

Báo cáo khoa học: "Heterotopic ossification – a long-term consequence of prolonged immobility"
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.